[{"orgOrder":0,"company":"Noucor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rupatadine Fumarate","moa":"Platelet activating factor receptor | Histamine H1 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Noucor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Noucor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noucor \/ Inapplicable"},{"orgOrder":0,"company":"Noucor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rupatadine Fumarate","moa":"Platelet activating factor receptor | Histamine H1 receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Noucor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Noucor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Noucor \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Noucor

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 16, 2024

                          Lead Product(s) : Rupatadine Fumarate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 27, 2024

                          Lead Product(s) : Rupatadine Fumarate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank